Board Evolution at BioAlliance to Support Its Growth Strategy

Published: May 20, 2011

BioAlliance Pharma’s (Paris:BIO) Board has approved the draft resolutions on Board changes, to be voted at the General Assembly Meeting on June 29, 2011. Following Mr. André Ulmann and Mr. Gilles Marrache expressed wishes not to pursue their board mandate due to personal constraints, the Board thanks them for their commitment and contribution to its work and will propose their replacement at next General Assembly Meeting respectively by the company Financière de la Montagne, the first BioAlliance’s shareholder, represented by Mr. Nicolas Trebouta, and by Mr. David Solomon.

Back to news